Fiocruz Amazônia, Instituto Leônidas e Maria Deane, Laboratório de Diagnóstico e Controle de Doenças Infecciosas na Amazônia, Amazonas, Manaus, Brazil.
Fiocruz, Instituto Oswaldo Cruz, Programa de Pós-Graduação Stricto Sensu em Biologia Celular e Molecular, Rio de Janeiro, Rio de Janeiro, Brazil.
Rev Inst Med Trop Sao Paulo. 2021 Jan 29;63:e11. doi: 10.1590/S1678-9946202163011. eCollection 2021.
Malaria represents a serious public health problem, presenting with high rates of incidence, morbidity and mortality in tropical and subtropical regions of the world. According to the World Health Organization, in 2018 there were 228 million cases and 405 thousand deaths caused by this disease in the world, affecting mainly children and pregnant women in Africa. Despite the programs carried out to control this disease, drug resistance and invertebrate vector resistance to insecticides have generated difficulties. An efficient vaccine against malaria would be a strategy with a high impact on the eradication and control of this disease. Researches aimed at developing vaccines have focused on antigens of high importance for the survival of the parasite such as the Circumsporozoite Surface Protein, involved in the pre-erythrocytic cycle during parasites invasion in hepatocytes. Currently, RTS'S is the most promising vaccine for malaria and was constructed using CSP; its performance was evaluated using two types of adjuvants: AS01 and AS02. The purpose of this review was to provide a bibliographic survey of historical researches that led to the development of RTS'S and its performance analysis over the decade. The search for new adjuvants to be associated with this antigen seems to be a way to obtain higher percentages of protection for a future malaria vaccine.
疟疾是一个严重的公共卫生问题,在世界上的热带和亚热带地区发病率、发病率和死亡率都很高。根据世界卫生组织的数据,2018 年全球有 2.28 亿例疟疾病例和 40.5 万人死亡,主要影响非洲的儿童和孕妇。尽管开展了控制这种疾病的项目,但药物耐药性和无脊椎动物对杀虫剂的耐药性带来了困难。一种有效的疟疾疫苗将是一种对消除和控制这种疾病具有重大影响的策略。针对疫苗开发的研究集中在寄生虫生存至关重要的抗原上,如环子孢子表面蛋白(Circumsporozoite Surface Protein),它参与寄生虫侵入肝细胞的红细胞前期循环。目前,RTS'S 是最有前途的疟疾疫苗,它使用 CSP 构建;其性能使用两种佐剂进行了评估:AS01 和 AS02。本综述的目的是对导致 RTS'S 发展的历史研究进行文献调查,并对其在过去十年中的表现进行分析。寻找与这种抗原相关的新佐剂似乎是获得未来疟疾疫苗更高保护率的一种方法。